The Longevity Question We Should Be Asking

The question of whether aesthetic medicine should engage with longevity has been answered for some time now. Our patients are already there, with or without us. The remaining question is whether we are going to claim intellectual ownership of this space or cede it to the wellness industry and inherit whatever framework they construct in our absence.

I do not love where things are heading by default. Walk the exhibition floor at any major aesthetic meeting in 2026 and you will see IV drip protocols sold next to injectables, peptide cocktails marketed alongside biostimulators, and ozone therapy or plasma exchange with mechanistic claims that significantly outrun their published evidence. Patients are paying meaningful sums for interventions whose risk-benefit profile has not been characterized in any rigorous way. Some of these products will turn out to be genuinely useful once the science catches up. Some will turn out to be elaborate placebos. Some will turn out to be net harmful. Right now, neither the patient nor most of the clinicians administering them can reliably distinguish between the three.

This is not a complaint about innovation. The molecular biology of aging is one of the most intellectually exciting frontiers in medicine, and the legitimate science around things like senolytic pathways, Nicotinamide adenine dinucleotide (NAD+) metabolism, cellular senescence, extracellular matrix dynamics, and the mitochondrial determinants of skin aging is producing genuinely important findings with real implications for dermatology and plastic surgery. I want our specialties to be central to this conversation. That is precisely why I am concerned about how the conversation is being conducted.

Here is the diagnostic question I think every clinician should apply to anything marketed under the longevity banner: what is the strongest piece of human evidence for this specific intervention, at this specific dose, by this specific route, for this specific endpoint? Not “the mechanism is plausible.” Not “there are studies showing the molecule does something interesting in vitro.” Not “patients report feeling better.” The actual clinical evidence, evaluated with the same rigor we would demand before approving a new filler or neurotoxin for facial use.

When you apply that question honestly, the longevity-aesthetics intersection sorts itself into 3 tiers. Tier 1: interventions with credible human data and a coherent dermatologic application. Topical retinoids and antioxidants with decades of clinical evidence. Energy-based devices with histological and longitudinal outcomes data. Biostimulators with prospective trials in human skin. Polynucleotide and emerging regenerative injectables where the published evidence has moved from in vitro to clinical. These are defensible recommendations. Tier 2: interventions with plausible mechanisms, early human data, and reasonable safety profiles, but where the dermatologic, aesthetic, or longevity endpoints are not yet well-characterized. Oral NAD+ precursors. Specific senolytic compounds in early clinical development. Some peptide therapies with established mechanisms but emerging cosmetic indications. These are defensible to discuss with patients as evolving science but not to actively recommend as established care. Tier 3: interventions where the marketing has substantially outpaced the evidence, and in some cases where the underlying premise itself is unsupported. Intravenous ozone therapy promoted for cellular rejuvenation, despite a clinical literature that ranges from absent to actively concerning when you account for embolic and oxidative risks. Therapeutic plasma exchange marketed as biological age reversal on the strength of rodent parabiosis data that has not translated to human longevity endpoints. Unregulated stem cell infusions from facilities that cannot characterize the cellular product they are administering. These are not defensible regardless of how compelling the vendor presentation is.

The aesthetic dermatology and plastic surgery community is uniquely positioned to bring evidentiary rigor to this space. We have the training, the regulatory literacy, and the patient relationships to do it. If we engage, longevity medicine becomes a serious clinical discipline with standards that protect patients. If we abdicate, it becomes a wellness category sold next to vitamin shots at the mall.

The longevity revolution is real. The question is who gets to define what counts as medicine within it. I would rather it be us than not.